glp 1 heart disease GLP-1: A Game-Changer for Health in Obesity Gut Hormones in Heart Failure

Our data reveal that the replacement of the tryptophan cage (trp-cage) of Exendin-4 tyrosine substituted at the amino terminus (ex-4Y1) with the C terminal undecapeptide sequence of Oxyntomodulin places the lysine 30 of the novel hybrid agonist in frame with the corresponding lysine residue in the native GIP sequence thereby converting the incretin to a GLP-1R-GIPR dual agonist

In contrast to RCTs, retrospective observational studies offer the benefit of capturing extensive patient data in real-world settings

Goes beyond appetite suppression to influence glucose metabolism and energy utilization creating a favorable environment for sustained weight loss

in clinical trials it led to a weight loss of 15% to 20% of body weight after 16 months

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study